FTI 276 TFA

Overview

FTI 276 TFA is a farnesyltransferase ( FTase ) inhibitor with an IC 50 of 0.5 nM, and it exhibits selectivity for FTase over geranylgeranyltransferase I ( GGTase I). FTI 276 TFA blocks the farnesylation of H-Ras and K-Ras4B , causes inactive Ras-Raf complexes to accumulate in the cytoplasm, and inhibits constitutive MAPK activation. FTI 276 TFA reduces the number, incidence and volume of tumors, and restricts the growth of tumors expressing activated K-ras . FTI 276 TFA can be used in research related to pulmonary adenoma.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Lung Adenocarcinoma | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Farnesyl Transferase | Products > Signaling Pathways > Ras | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-15873A
• CAS No.: 1217471-51-6
• Molecular Formula: C23H28F3N3O5S2
• Molecular Weight: 547.61
• Purity: 98.31%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution
• Availability: In-stock

Source

Original product source